Ameriprise
PCVX icon

Ameriprise’s Vaxcyte PCVX Stock Holding History

Ameriprise’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.6M Buy
440,505
+329,519
+297% +$17.9M 0.01% 1357
2026
Q1 		$6.45M Sell
110,986
-194,208
-64% -$10.5M ﹤0.01% 2268
2025
Q4 		$14.1M Sell
305,194
-69,708
-19% -$3.12M ﹤0.01% 1663
2025
Q3 		$13.5M Buy
374,902
+44,231
+13% +$1.47M ﹤0.01% 1683
2025
Q2 		$10.8M Sell
330,671
-347,910
-51% -$11.4M ﹤0.01% 1762
2025
Q1 		$25.6M Sell
678,581
-38,192
-5% -$3.05M 0.01% 1169
2024
Q4 		$58.7M Buy
716,773
+366,622
+105% +$36.4M 0.02% 758
2024
Q3 		$40M Buy
350,151
+72,387
+26% +$6.52M 0.01% 946
2024
Q2 		$21M Buy
277,764
+159,231
+134% +$10.8M 0.01% 1252
2024
Q1 		$8.1M Buy
118,533
+76,008
+179% +$5.26M ﹤0.01% 1984
2023
Q4 		$2.67M Buy
42,525
+30,846
+264% +$1.6M ﹤0.01% 2737
2023
Q3 		$595K Buy
+11,679
New +$576K ﹤0.01% 3338

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ameriprise's PCVX Position: Q2 2026 in Review

Ameriprise increased its Vaxcyte (PCVX) stake by 297% in Q2 2026, buying an estimated $17.9M and bringing the position to 440,505 shares worth $25.6M. The position accounts for 0.01% of the portfolio, ranked #1357.

Ameriprise first reported a position in PCVX in Q3 2023 and has held it in 12 quarters since. The position peaked at $58.7M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Ameriprise held 440,505 shares of Vaxcyte worth $25.6M as of Q2 2026.
  • Ameriprise bought 329,519 Vaxcyte shares in Q2 2026, an estimated $17.9M.
  • Vaxcyte made up 0.01% of Ameriprise's portfolio in Q2 2026, its #1357 holding.
  • Ameriprise first reported a position in Vaxcyte in Q3 2023 and has held it in 12 quarters since.
  • Ameriprise's Vaxcyte position peaked at $58.7M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.